Key Concepts and Critical Issues on Epoetin and Filgrastim Biosimilars. A Position Paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation

Overview

Journal Haematologica

Specialty Hematology

Date 2011 Jul 2

PMID 21719882

Citations 20

Authors

Giovanni Barosi

Alberto Bosi

Maria P Abbracchio

Romano Danesi

Armando Genazzani

Paolo Corradini

Fabrizio Pane

Sante Tura

Affiliations

Soon will be listed here.

Citing Articles

Mohd Sani N, Aziz Z, Kamarulzaman A BioDrugs. 2024; 38(3):405-423.

PMID: 38472644 DOI: 10.1007/s40259-024-00649-2.

Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective.

Khan M, Aseeri M, Alshamrani M, Alnatsheh A, Alhamdan H Glob J Qual Saf Healthc. 2023; 3(1):22-29.

PMID: 37440966 PMC: 10335781. DOI: 10.4103/JQSH.JQSH_15_19.

Bachu R, Abou-Dahech M, Balaji S, Boddu S, Amos S, Singh V Cancer Rep (Hoboken). 2022; 5(11):e1720.

PMID: 36195576 PMC: 9675387. DOI: 10.1002/cnr2.1720.

Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes.

Vetro C, di Giacomo V, Mannina D, Magrin S, Mule A, Mitra M J Clin Med. 2022; 11(6).

PMID: 35329991 PMC: 8951463. DOI: 10.3390/jcm11061665.

ATR-FTIR spectroscopy and spectroscopic imaging for the analysis of biopharmaceuticals.

Tiernan H, Byrne B, Kazarian S Spectrochim Acta A Mol Biomol Spectrosc. 2020; 241:118636.

PMID: 32610215 PMC: 7308041. DOI: 10.1016/j.saa.2020.118636.

References

Waller C, Semiglazov V, Tjulandin S, Bentsion D, Chan S, Challand R . A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie. 2010; 33(10):504-11. DOI: 10.1159/000319693. View

Wiecek A, Ahmed I, Scigalla P, Koytchev R . Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. Adv Ther. 2010; 27(12):941-52. DOI: 10.1007/s12325-010-0080-z. View

Atkins H . Hematopoietic SCT for the treatment of multiple sclerosis. Bone Marrow Transplant. 2010; 45(12):1671-81. DOI: 10.1038/bmt.2010.168. View

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R . Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008; 24(3):625-37. DOI: 10.1185/030079908X273264. View

Kuhlmann M, Covic A . The protein science of biosimilars. Nephrol Dial Transplant. 2006; 21 Suppl 5:v4-8. DOI: 10.1093/ndt/gfl474. View

Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A . Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008; 25(11):1215-28. DOI: 10.1007/s12325-008-0111-1. View

Mellstedt H, Niederwieser D, Ludwig H . The challenge of biosimilars. Ann Oncol. 2007; 19(3):411-9. DOI: 10.1093/annonc/mdm345. View

Lonnemann G, Wrenger E . Biosimilar epoetin zeta in nephrology - a single-dialysis center experience. Clin Nephrol. 2010; 75(1):59-62. View

Weigang-Kohler K, Vetter A, Thyroff-Friesinger U . HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie. 2009; 32(4):168-74. DOI: 10.1159/000200783. View

10.

FERGUSON J . The NIH Consensus Development Program. The evolution of guidelines. Int J Technol Assess Health Care. 1996; 12(3):460-74. View

11.

Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, Del Giglio A . XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma. 2009; 50(3):374-9. DOI: 10.1080/10428190902756081. View

12.

Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazao J, Goldsmith D . Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant. 2008; 23(12):3731-7. DOI: 10.1093/ndt/gfn519. View

13.

Haag-Weber M, Vetter A, Thyroff-Friesinger U . Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009; 72(5):380-90. View

14.

Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M . Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010; 27(2):105-17. DOI: 10.1007/s12325-010-0012-y. View

15.

Looper Y . Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics. Curr Opin Drug Discov Devel. 2010; 13(2):247-56. View

16.

Bouchet J, Brunet P, Canaud B, Chanliau J, Combe C, Deray G . [Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique]. Nephrol Ther. 2008; 5(1):61-6. DOI: 10.1016/j.nephro.2008.10.006. View

17.

Niederwieser D, Schmitz S . Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol. 2010; 86(4):277-88. PMC: 3085072. DOI: 10.1111/j.1600-0609.2010.01566.x. View

18.

Del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H . XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008; 8:332. PMC: 2628928. DOI: 10.1186/1471-2407-8-332. View

19.

Engert A, Del Giglio A, Bias P, Lubenau H, Gatzemeier U, Heigener D . Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie. 2009; 32(10):599-604. DOI: 10.1159/000232580. View

20.

Tamilvanan S, Raja N, Sa B, Basu S . Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J Drug Target. 2010; 18(7):489-98. DOI: 10.3109/10611861003649746. View